- Investing Ideas
- U.S. Pharmaceuticals & Biotech Buy the Dip
U.S. Pharmaceuticals & Biotech Buy the Dip
Results
12
Companies which have seen a dip in the last 7 days after continued gains and are looking undervalued based on Snowflake checks.
12 companies
Celcuity
Market Cap: US$4.3b
A clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States.
CELC
US$88.38
7D
-14.8%
1Y
552.7%
Celldex Therapeutics
Market Cap: US$2.8b
A biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases.
CLDX
US$35.35
7D
-8.3%
1Y
60.2%
AnaptysBio
Market Cap: US$1.7b
A clinical-stage biotechnology company, focuses in delivering immunology therapeutics for autoimmune and inflammatory diseases in the United States.
ANAB
US$58.00
7D
-16.9%
1Y
121.6%
Solid Biosciences
Market Cap: US$858.5m
Develops therapies for neuromuscular and cardiac diseases in the United States.
SLDB
US$8.72
7D
-10.3%
1Y
36.9%
Design Therapeutics
Market Cap: US$785.1m
A clinical-stage biopharmaceutical company, research, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States.
DSGN
US$12.57
7D
-9.3%
1Y
210.4%
Ironwood Pharmaceuticals
Market Cap: US$635.4m
A biotechnology company, focuses on the development and commercialization of therapies for gastrointestinal (GI) and rare diseases in the United States and internationally.
IRWD
US$3.86
7D
-8.3%
1Y
405.6%
Sutro Biopharma
Market Cap: US$390.6m
Operates as an oncology company.
STRO
US$23.57
7D
-15.3%
1Y
194.6%
Opus Genetics
Market Cap: US$270.0m
A clinical-stage biopharmaceutical company, develops gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs) and other types of therapies for additional ophthalmic disorders.
IRD
US$3.27
7D
-14.2%
1Y
174.8%
Q32 Bio
Market Cap: US$255.2m
A clinical-stage biotechnology company, develops novel biologics to restore healthy immune balance in patients with alopecia areata and other autoimmune and inflammatory diseases driven by pathological immune dysfunction.
QTTB
US$15.05
7D
-29.6%
1Y
590.4%
Precision BioSciences
Market Cap: US$203.1m
A clinical stage gene editing company, develops in vivo gene editing therapies for gene edits, including gene insertion, excision, and elimination in the United States.
DTIL
US$7.87
7D
-8.4%
1Y
69.2%
Acumen Pharmaceuticals
Market Cap: US$162.5m
A clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer’s disease.
ABOS
US$2.25
7D
-14.8%
1Y
45.2%
LeonaBio
Market Cap: US$67.8m
LeonaBio, Inc., clinical-stage biopharmaceutical company, engages in the development of novel therapeutics for high unmet medical needs, including treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis.
LONA
US$7.22
7D
-26.0%
1Y
67.5%